Skip to main content

Biosyent Inc.(RX-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low14.640
Day High14.900
Open:14.640
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
BioSyent to Present at 2026 Bloom Burton & Co. Healthcare Investor Conference
FeraMAX is Canada's Top-Ranked Iron Supplement for 11 Consecutive Years
BioSyent Announces Grant of Restricted Share Units
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2025
BioSyent Schedules Fourth Quarter and Full Year 2025 Earnings Release for March 19, 2026
BioSyent Announces Closing of the Acquisition of Oral Science Inc.
Upcoming Meeting Dates - February 16, 2026
BioSyent to Acquire Oral Science Inc.
BioSyent Declares First Quarter 2026 Dividend
BioSyent Announces Renewal of Normal Course Issuer Bid
BioSyent Releases Financial Results for Q3 and YTD 2025
BioSyent Declares Fourth Quarter 2025 Dividend
BioSyent Releases Financial Results for Q2 and H1 2025
BioSyent Declares Third Quarter 2025 Dividend
BioSyent Schedules Q2 and H1 2025 Earnings Release for August 21, 2025
BioSyent Releases Financial Results for First Quarter 2025
BioSyent Schedules First Quarter Earnings Release for May 15, 2025
BioSyent to Present at 2025 Bloom Burton & Co. Healthcare Investor Conference
BioSyent to Present at LD Micro New York Investor Conference
FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Tenth Consecutive Year
BioSyent Announces Grant of Restricted Share Units
BioSyent Schedules Fourth Quarter and Full Year 2024 Earnings Release for March 13, 2025
BioSyent Declares First Quarter 2025 Dividend
BioSyent Announces Renewal of Normal Course Issuer Bid
BioSyent Releases Financial Results for Q3 and YTD 2024
BioSyent Declares Fourth Quarter 2024 Dividend
BioSyent Schedules Q3 and YTD 2024 Earnings Release for November 20, 2024
BioSyent Announces Agreement to Purchase Tibelia® (tibolone) Assets

Profile

Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It markets and delivers a diverse range of healthcare products, including over-the-counter, behind-the-counter, and prescription options. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX Pd, Inofolic, Gelclair, Cathejell, RepaGyn, Proktis-M, and Tibella. The company derives revenue from pharmaceutical and insecticide business. Geographically, it derives maximum revenue from Canada and also has its presence internationally.